5 Key Takeaways

• 1

  Researchers are enhancing CAR-NK cell therapies by modifying receptor architecture and controlling drug exposure.

• 2

  CD19-targeted CAR-NK-92 cells showed antigen-specific killing of CD19-positive leukemia and lymphoma cell lines.

• 3

  Transcriptional profiling revealed that different CAR configurations engage NK-associated activation programs variably.

• 4

  Transient exposure to dasatinib suppressed CAR-NK activity but increased cytotoxicity and cytokine production post-withdrawal.

• 5

  The study suggests that receptor engineering and pharmacologic modulation can improve next-generation allogeneic NK products.